Dr. Gunjan Shah, MD, MS
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Multiple Myeloma
Studies Lymphoma
9 reported clinical trials
14 drugs studied
Affiliated Hospitals
Clinical Trials Gunjan Shah, MD, MS is currently running
Ide-cel (bb2121)
for Multiple Myeloma
The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.
Recruiting1 award Phase 29 criteria
Melphalan
for Lymphoma
The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT. Standard dose is fixed for everybody and is calculated using height and weight. The population PK model, tested in this study, uses information based on people who have previously received melphalan and aims to calculate an optimal dose separately for each person. Study researchers think that the dose calculated using the population PK model may still be effective but have less side effects than the standard melphalan dose.
Recruiting1 award Phase 12 criteria
More about Gunjan Shah, MD, MS
Clinical Trial Related3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Gunjan Shah, MD, MS has experience with
- Melphalan
- Siltuximab
- Ide-cel (bb2121)
- Plinabulin
- The M.D. Anderson Symptom Inventory (MDASI)
- Autologous Hematopoietic Cell Transplantation
Breakdown of trials Gunjan Shah, MD, MS has run
Multiple Myeloma
Amyloidosis
AL Amyloidosis
Central Nervous System Hodgkin Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gunjan Shah, MD, MS specialize in?
Gunjan Shah, MD, MS focuses on Multiple Myeloma and Lymphoma. In particular, much of their work with Multiple Myeloma has involved treating patients, or patients who are undergoing treatment.
Is Gunjan Shah, MD, MS currently recruiting for clinical trials?
Yes, Gunjan Shah, MD, MS is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Gunjan Shah, MD, MS has studied deeply?
Yes, Gunjan Shah, MD, MS has studied treatments such as Melphalan, Siltuximab, Ide-cel (bb2121).
What is the best way to schedule an appointment with Gunjan Shah, MD, MS?
Apply for one of the trials that Gunjan Shah, MD, MS is conducting.
What is the office address of Gunjan Shah, MD, MS?
The office of Gunjan Shah, MD, MS is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.